Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Open accessPublished version of a preprint
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Loss-of-function mutations in JAK1/2 can lead to acquired resistance to anti-programmed death protein 1 (PD-1) therapy. We reasoned that they may also be involved in primary resistance to anti–PD-1 therapy. JAK1/2-inactivating mutations were noted in tumor biopsies of 1 of 23 patients with melanoma and in 1 of 16 patients with mismatch repair–deficient colon cancer treated with PD-1 blockade. Both cases had a high mutational load but did not respond to anti–PD-1 therapy. Two out of 48 human melanoma cell lines had JAK1/2 mutations, which led to a lack of PD-L1 expression upon interferon gamma exposure mediated by an inability to signal through the interferon gamma receptor pathway. JAK1/2 loss-of-function alterations in The Cancer Genome Atlas confer adverse outcomes in patients. We propose that JAK1/2 loss-of-function mutations are a genetic mechanism of lack of reactive PD-L1 expression and response to interferon gamma, leading to primary resistance to PD-1 blockade therapy. Significance: A key functional result from somatic JAK1/2 mutations in a cancer cell is the inability to respond to interferon gamma by expressing PD-L1 and many other interferon-stimulated genes. These mutations result in a genetic mechanism for the absence of reactive PD-L1 expression, and patients harboring such tumors would be unlikely to respond to PD-1 blockade therapy. Cancer Discov; 7(2); 188–201. ©2016 AACR. See related commentary by Marabelle et al., p. 128. This article is highlighted in the In This Issue feature, p. 115
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This implies that the inactivation mutations of JAK1 and JAK2 block the IFN-γ signaling pathway, leading to downregulation of tumor PD-L1 expression, so it would be unnecessary to attempt anti-PD-L1 therapy in this case.”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [210]
In the citing paper
“JAK1/2-inactivating mutations reduce programmed death ligand 1 (PD-L1) and MHC I expression in mouse and human CRC [33,210].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [210]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 1×
“The results are based upon data generated by the TCGA Research Network and made available through the NCI Genomic Data Commons and cBioPortal (45, 46).”
MethodAdverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · cited 1×
“The results are based upon data generated by the TCGA Research Network and made available through the NCI Genomic Data Commons and cBioPortal (45, 46).”
MethodThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 2×
“However, interferon gamma also provides the signal that allows cancer cells to inactivate antitumor T cells by the adaptive expression of PD-L1 (9), thereby specifically escaping their cytotoxic effects (12).”
BackgroundSelf-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationThe Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 1×
“Frequency of JAK Loss of Function Mutations in Cell Lines of Multiple Histologies We then analyzed data from the Cancer Cell Line Encyclopedia (CCLE) from cBioPortal to determine the frequency of homozygous putative loss of function mutations in JAK1/2 in 905 cancer cell lines (25).”
MethodMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 5×
“This remarkable antitumor activity is explained by the reactivation of tumor antigen-specific T cells that were previously inactive due to the interaction between PD-1 and its ligand PD-L1 expressed by cancer cells (1, 9-12).”
BackgroundMethodInfluentialSelf-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“Blocking the programmed death 1 (PD-1) negative immune receptor results in unprecedented rates of long lasting anti-tumor activity in patients with metastatic cancers of different histologies, including melanoma, Hodgkin’s disease, Merkel cell, head and neck, lung, esophageal, gastric, liver, kidney, ovarian, bladder…”
BackgroundPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · cited 1×
“Blocking the programmed death 1 (PD-1) negative immune receptor results in unprecedented rates of long lasting anti-tumor activity in patients with metastatic cancers of different histologies, including melanoma, Hodgkin’s disease, Merkel cell, head and neck, lung, esophageal, gastric, liver, kidney, ovarian, bladder…”
BackgroundSelf-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 1×
“Blocking the programmed death 1 (PD-1) negative immune receptor results in unprecedented rates of long lasting anti-tumor activity in patients with metastatic cancers of different histologies, including melanoma, Hodgkin’s disease, Merkel cell, head and neck, lung, esophageal, gastric, liver, kidney, ovarian, bladder…”
BackgroundCancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393 · cited 2×
“5 acquired resistance to immunotherapy in mouse models (15-17) and in patients treated with the anti-CTLA-4 antibody ipilimumab who did not respond to therapy (18).”
BackgroundPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 2×
“This remarkable antitumor activity is explained by the reactivation of tumor antigen-specific T cells that were previously inactive due to the interaction between PD-1 and its ligand PD-L1 expressed by cancer cells (1, 9-12).”
BackgroundSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., Miller, C. A., Mardis, E. R., Ding, L., & Wilson, R. K. (2012) · Genome Research · doi:10.1101/gr.129684.111 · Cited by 4,905 · cited 1×
“6) (41), and the GATK-HC) for SNVs, and those called by both Varscan2 and the GATK-HC for insertions/deletions.”
MethodThe future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · cited 1×
“be a target for a T cell response, the presence of immune suppressive factors in the tumor microenviroment that exclude T cells in tumors or that lead to alteration of T cell function, presence of immune suppressive cells such as T regulatory or myeloid-derived suppressor cells, or cancers that have specific genetic s…”
BackgroundRosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · cited 2×
“JAK Loss of Function Mutations in Primary Resistance to PD-1 Blockade in Patients with Metastatic Melanoma Recent data indicates that tumors with high mutational burden are more likely to have clinical responses to PD-1 blockade therapy (6, 19-21).”
BackgroundPD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560 · cited 2×
“Blocking the programmed death 1 (PD-1) negative immune receptor results in unprecedented rates of long lasting anti-tumor activity in patients with metastatic cancers of different histologies, including melanoma, Hodgkin’s disease, Merkel cell, head and neck, lung, esophageal, gastric, liver, kidney, ovarian, bladder…”
BackgroundMechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491 · cited 1×
“JAK kinases mediate signaling from many cytokine receptors, but the commonality between JAK1 and JAK2 homozygous loss of function mutations is that they are both required for signaling upon exposure to interferon gamma (27).”
BackgroundGenomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · cited 2×
“be a target for a T cell response, the presence of immune suppressive factors in the tumor microenviroment that exclude T cells in tumors or that lead to alteration of T cell function, presence of immune suppressive cells such as T regulatory or myeloid-derived suppressor cells, or cancers that have specific genetic s…”
BackgroundSelf-citationMutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · cited 4×
“However, as the baseline expression of MHC class I, proteasome subunits and TAP transporters is unchanged, then tumor antigen presentation to T cells was not impaired (14).”
BackgroundInfluentialSelf-citationWolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222 · cited 1×
“The protocol allowed to proceed beyond initial progression at the restaging scans at 12 weeks and have repeated imaging scans 4 weeks later following the immune-related response criteria (irRC) (36).”
MethodClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065 · cited 1×
“al (43) to calculate the fraction of mutated chromosomal copies while adjusting”
BackgroundMelanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · cited 1×
“be a target for a T cell response, the presence of immune suppressive factors in the tumor microenviroment that exclude T cells in tumors or that lead to alteration of T cell function, presence of immune suppressive cells such as T regulatory or myeloid-derived suppressor cells, or cancers that have specific genetic s…”
BackgroundMPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381 · cited 1×
“org/uc/item/0cj1q8m0 Journal Cancer discovery, 7(2) ISSN 2159-8274 Authors Shin, Daniel Sanghoon Zaretsky, Jesse M Escuin-Ordinas, Helena et al.”
BackgroundMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192 · cited 2×
“Samples were immediately fixed in formalin followed by paraffin embedding, and when there was additional sterile piece of the tumor processed for snapfreezing in liquid nitrogen and to establish a cell line as previously described (33-35).”
BackgroundMethodSelf-citationTaube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157 · cited 1×
“This remarkable antitumor activity is explained by the reactivation of tumor antigen-specific T cells that were previously inactive due to the interaction between PD-1 and its ligand PD-L1 expressed by cancer cells (1, 9-12).”
BackgroundSelf-citationDemonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300 · cited 2×
“In primary resistance to checkpoint blockade therapy with the anti–CTLA-4 antibody ipilimumab, there is a higher frequency of mutations in the several molecules involved in the interferon signaling pathway (18).”
BackgroundPD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258 · cited 1×
“Blocking the programmed death 1 (PD-1) negative immune receptor results in unprecedented rates of long lasting anti-tumor activity in patients with metastatic cancers of different histologies, including melanoma, Hodgkin’s disease, Merkel cell, head and neck, lung, esophageal, gastric, liver, kidney, ovarian, bladder…”
BackgroundSelf-citationBeroukhim, R., Getz, G., Nghiemphu, L., Barretina, J., Hsueh, T., Linhart, D., Vivanco, I., Lee, J. C., Huang, J. H., Alexander, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710052104 · Cited by 1,075
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., et al. (2016) · JAMA · doi:10.1001/jama.2016.4059 · Cited by 1,069 · cited 2×
“Tumor samples Tumor biopsies were obtained from a subset of patients enrolled in a phase 1 expansion clinical trial with pembrolizumab after signing a written informed consent (32).”
BackgroundMethodSelf-citationTHE IFNγ RECEPTOR:A Paradigm for Cytokine Receptor Signaling
Bach, E. A., Aguet, M., & Schreiber, R. D. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.563 · Cited by 1,034 · cited 1×
“Most of these genes lead to beneficial antitumor effects, such as increased antigen presentation through inducible proteasome subunits, transporters associated with antigen processing (TAP) and the major histocompatibility complex (MHC), as well as increased production of chemokines attracting T cells and direct tumor…”
BackgroundAcquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0642 · Cited by 982 · cited 1×
“Methods were modified from reference (39); specifically the substitution the GATK-HaplotypeCaller (HC, v3.”
MethodSelf-citationRodig, S. J., Meraz, M. A., White, J. M., Lampe, P. A., Riley, J. K., Arthur, C. D., King, K. L., Sheehan, K. C. F., Yin, L., Pennica, D., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81166-6 · Cited by 853 · cited 1×
“9 that JAK1 (disabled in M395) is required to propagate signaling downstream of the interferon alpha/beta and gamma receptors, while JAK2 (disabled in M368) is required for signaling downstream only from the interferon gamma receptor (22-24).”
BackgroundSequenza: allele-specific copy number and mutation profiles from tumor sequencing data
Favero, F., Joshi, T., Marquard, A. M., Birkbak, N. J., Krzystanek, M., Li, Q., Szallasi, Z., & Eklund, A. C. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu479 · Cited by 836 · cited 1×
“Local tumor Copy Number (CNt,) Tumor Fraction (purity, or p) and Stromal Fraction (1-p) were produced by Sequenza (44), which uses both depth-ratio and SNP minor B-allele frequencies to estimate tumor ploidy, percent tumor content and perform allele-specific copy number variation analysis.”
MethodThe protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction
Müller, M., Briscoe, J., Laxton, C., Guschin, D., Ziemiecki, A., Silvennoinen, O., Harpur, A. G., Barbieri, G., Witthuhn, B. A., Schindler, C., et al. (1993) · Nature · doi:10.1038/366129a0 · Cited by 760
Adaptive Immune Resistance: How Cancer Protects from Immune Attack
Ribas, A. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0563 · Cited by 613 · cited 3×
“However, interferon gamma also provides the signal that allows cancer cells to inactivate antitumor T cells by the adaptive expression of PD-L1 (9), thereby specifically escaping their cytotoxic effects (12).”
BackgroundSelf-citationWatling, D., Guschin, D., Müller, M., Silvennoinen, O., Witthuhn, B. A., Quelle, F. W., Rogers, N. C., Schindler, C., Stark, G. R., Ihle, J. N., et al. (1993) · Nature · doi:10.1038/366166a0 · Cited by 533 · cited 1×
“9 that JAK1 (disabled in M395) is required to propagate signaling downstream of the interferon alpha/beta and gamma receptors, while JAK2 (disabled in M368) is required for signaling downstream only from the interferon gamma receptor (22-24).”
BackgroundWeb‐Based Analysis and Publication of Flow Cytometry Experiments
Kotecha, N., Krutzik, P. O., & Irish, J. M. (2010) · Current Protocols in Cytometry · doi:10.1002/0471142956.cy1017s53 · Cited by 511 · cited 1×
“The FCS files obtained by LRSII were analyzed using the online flow cytometry program (cytobank) (37).”
MethodOncotator: Cancer Variant Annotation Tool
Ramos, A. H., Lichtenstein, L., Gupta, M., Lawrence, M. S., Pugh, T. J., Saksena, G., Meyerson, M., & Getz, G. (2015) · Human Mutation · doi:10.1002/humu.22771 · Cited by 501
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Atefi, M., Avramis, E., Lassen, A., Wong, D. J. L., Robert, L., Foulad, D., Cerniglia, M., Titz, B., Chodon, T., Graeber, T. G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2797 · Cited by 334 · cited 2×
“Samples were immediately fixed in formalin followed by paraffin embedding, and when there was additional sterile piece of the tumor processed for snapfreezing in liquid nitrogen and to establish a cell line as previously described (33-35).”
BackgroundMethodSelf-citationIFN Unresponsiveness in LNCaP Cells Due to the Lack of JAK1 Gene Expression
Dunn, G. P., Sheehan, K. C. F., Old, L. J., & Schreiber, R. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4316 · Cited by 173 · cited 1×
“Beyond a genetic mutation that prevented expression of JAK1/2, it is also possible that epigenetic silencing of JAKs could result in lack of response to interferon gamma, as previously reported for the LNCAP cell line (29).”
BackgroundWong, D. J., Robert, L., Atefi, M. S., Lassen, A., Avarappatt, G., Cerniglia, M., Avramis, E., Tsoi, J., Foulad, D., Graeber, T. G., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-194 · Cited by 122 · cited 2×
“Samples were immediately fixed in formalin followed by paraffin embedding, and when there was additional sterile piece of the tumor processed for snapfreezing in liquid nitrogen and to establish a cell line as previously described (33-35).”
BackgroundMethodSelf-citationFish, E. N., & Platanias, L. C. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0450 · Cited by 87 · cited 2×
“As the interferon gamma receptor pathway downstream of JAK1/2 controls the expression of chemokines with potent chemoattractant effect on T cells, such as CXCL9, CXCL10 and CXCL11 (28), it is possible that an important effect of JAK1/2 loss may result in lack of T cell infiltrates.”
BackgroundRen, Y., Zhang, Y., Liu, R. Z., Fenstermacher, D. A., Wright, K. L., Teer, J. K., & Wu, J. (2013) · Scientific Reports · doi:10.1038/srep03042 · Cited by 71 · cited 2×
“The highest frequency of mutations was in endometrial cancers, as described previously (26).”
BackgroundEscuin-Ordinas, H., Atefi, M., Fu, Y., Cass, A., Ng, C., Huang, R. R., Yashar, S., Comin-Anduix, B., Avramis, E., Cochran, A. J., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2013.11.005 · Cited by 41 · cited 1×
“Western blotting was performed as described previously (38).”
MethodSelf-citationMazzolini, G. D., Narvaiza, I., Martínez‐Cruz, L. A., Arina, A., Barajas, M. A., Galofré, J. C., Qian, C., Mato, J. M., Prìeto, J., & Melero, I. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301957 · Cited by 38 · cited 1×
“5 acquired resistance to immunotherapy in mouse models (15-17) and in patients treated with the anti-CTLA-4 antibody ipilimumab who did not respond to therapy (18).”
Background
Cited by
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Self-citationPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
“The interferon-gamma pathway is emerging as a key player in primary, adaptive, and acquired resistance to checkpoint blockade therapy (Gao et al., 2016; Pardoll, 2012; Ribas, 2015; Shin et al., 2016; Zaretsky et al., 2016).”
Self-citationExosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., Yu, Z., Yang, J., Wang, B., Sun, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0392-8 · Cited by 2,813
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Metadata
- Authors
- Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., Palaskas, N., Rodriguez, G. A., Parisi, G., Azhdam, A., Chmielowski, B., Cherry, G., Seja, E., Berent-Maoz, B., Shintaku, I. P., Le, D. T., Pardoll, D. M., Diaz, L. A., Tumeh, P. C., Graeber, T. G., Lo, R. S., Comin-Anduix, B., & Ribas, A.
- Affiliations
- University of California, Los Angeles (US)
- 1University of California, Los Angeles (UCLA), Los Angeles, California.
- Johns Hopkins University (US)
- Corresponding author
- Ribas, Antoni
- ORCID
- Venue
- Cancer Discovery
- Published
- 2017-02-01
- Volume
- 7
- Issue
- 2
- Pages
- 188-201
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5296316
- OpenAlex
- W2557336488
- Cited by
- 1,337
- References
- 49
- Citations by year
- 2026: 110 · 2025: 123 · 2024: 101 · 2023: 152 · 2022: 153 · 2021: 182 · 2020: 160 · 2019: 129 · 2018: 133 · 2017: 91
- FWCI
- 63.65
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR000124, 5t32ar058921-04, UL1TR001881)
- National Cancer Institute (P01CA168585, R01CA199205, T32CA009297, T32CA009120, R35CA197633)
- National Institute of General Medical Sciences (T32GM008042)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32-AR058921)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- anti-PD-1 therapy, primary resistance, loss-of-function mutations, melanoma, PD-L1 expression, interferon-gamma signaling, interferon-stimulated genes, immune checkpoint inhibitors, tumor mutational burden
- MeSH terms
- Colonic Neoplasms, Humans, Interferon-gamma, Melanoma, Mutation, Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Cell Line, Tumor, Janus Kinase 1, Janus Kinase 2, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.